Antengene-B (06996) rose more than 6%, with the stock up 6.4% to HK$3.66 at the time of writing, recording a turnover of HK$13.326 million. The company announced this morning that it has entered into a clinical collaboration agreement with Junshi Bio. The partnership will focus on exploring the combined therapeutic potential of Antengene's ATG-037, an oral CD73 small molecule inhibitor, and Junshi Bio's JS207, an anti-PD-1/VEGF bispecific antibody, in cancer patients in mainland China. The company noted that with resistance to immune checkpoint inhibitors becoming a major clinical challenge, ATG-037 has demonstrated strong ability to reverse resistance when used in combination with such inhibitors in Phase I trials. The collaboration aims not only to validate the synergistic effects of the two innovative drugs but also to break through the current efficacy limitations of immunotherapy through a "three-axis" strategy combining immune activation, anti-angiogenesis, and adenosine pathway inhibition, with the goal of significantly extending overall survival for cancer patients.